University of Health Sciences, Ankara City Hospital, Department of Thoracic Surgery, Bilkent, Ankara, Turkey.
Istanbul Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Department of Infectious Diseases, Istanbul, Turkey.
Acta Clin Croat. 2022 Dec;61(4):655-660. doi: 10.20471/acc.2022.61.04.12.
In our study, we examined the effect of COVID-19 vaccination on the incidence of pneumothorax in intensive care patients over age 65. COVID-19 intensive care patients that presented to our department between April 2020 and May 2021 during the COVID-19 pandemic were evaluated retrospectively. Patients were divided into two main groups, i.e., before and after the vaccination period. Patients were evaluated retrospectively for the following parameters: gender, age, side of pneumothorax, mortality, discharge, comorbidity, and additional pleural complications. The total number of patients was 87, i.e., 66 patients before vaccination and 21 patients after vaccination. When patients in the pre- and post-vaccination period were compared, there was a significant difference in the incidence of pneumothorax between the two groups (p<0.05). Pneumothorax was less common after vaccination. When patients with pneumothorax and tube thoracostomy were evaluated according to pre- and post-vaccination mortality, mortality was significantly higher (89%) in the pre-vaccination period (p<0.05). We consider that COVID-19 vaccines used in patients aged over 65 reduced the incidence of pleural complications, especially pneumothorax. We think that mortality due to pneumothorax in patients over 65 years of age was lower during the vaccination period. In addition, we think that bilateral pneumothorax was more common in the non-vaccinated period. As a result, we think that life-threatening pneumothorax and similar complications could be reduced by increasing the number of vaccines made in the COVID-19 pandemic and spreading it around the world.
在我们的研究中,我们研究了 COVID-19 疫苗接种对 65 岁以上重症监护患者气胸发生率的影响。我们回顾性评估了 2020 年 4 月至 2021 年 5 月 COVID-19 大流行期间在我们部门就诊的 COVID-19 重症监护患者。患者分为两个主要组,即接种疫苗前和接种疫苗后。我们回顾性评估了以下参数:性别、年龄、气胸侧、死亡率、出院、合并症和其他胸膜并发症。总共有 87 名患者,即接种疫苗前 66 名患者和接种疫苗后 21 名患者。当比较接种疫苗前和接种疫苗后两组患者时,两组之间气胸发生率有显著差异(p<0.05)。接种后气胸较少见。当根据接种疫苗前后的气胸和胸腔管引流患者死亡率进行评估时,接种前死亡率显著更高(89%)(p<0.05)。我们认为,65 岁以上患者使用的 COVID-19 疫苗降低了胸膜并发症的发生率,特别是气胸。我们认为,接种疫苗期间 65 岁以上患者的气胸死亡率较低。此外,我们认为非接种期间双侧气胸更常见。因此,我们认为通过增加 COVID-19 大流行期间生产的疫苗数量并在全球范围内传播,可以减少威胁生命的气胸和类似并发症。